Catalyst Pharmaceuticals, Inc. (CPRX)

Market Cap	2.67B
Revenue (ttm)	534.65M
Net Income (ttm)	197.35M
Shares Out	121.98M
EPS (ttm)	1.57
PE Ratio	13.93
Forward PE	15.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,001,355
Open	21.43
Previous Close	21.63
Day's Range	21.31 - 22.06
52-Week Range	15.26 - 26.58
Beta	0.66
Analysts	Strong Buy
Price Target	32.83 (+50.25%)
Earnings Date	Aug 6, 2025

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2006
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: CPRX
• Website: https://catalystpharma.com

Financial Performance

In 2024, Catalyst Pharmaceuticals's revenue was $491.73 million, an increase of 23.49% compared to the previous year's $398.20 million. Earnings were $163.89 million, an increase of 129.50%.

Analyst Summary

According to 6 analysts, the average rating for CPRX stock is "Strong Buy." The 12-month stock price target is $32.83, which is an increase of 50.25% from the latest price.

Price Target

$32.83

(50.25% upside)

Analyst Consensus: Strong Buy